Company intelligence / Profile preview

Fixx Pharmaceuticals

Las Vegas, Nevada, United States

Ownership: Private
Development stage: Other

Overview

Fixx Pharmaceuticals is a private biotechnology company focused on developing gene-editing therapies for hemophilia and other inherited bleeding disorders. The company has described CRISPR-based therapeutic development as its core approach and has positioned hemophilia as its lead disease focus. Publicly available information indicates the business launched in 2020 with operations in Las Vegas, Nevada, and California. The company appears to be at an early preclinical stage, with limited disclosed pipeline detail beyond its stated goal of developing potentially curative therapies for bleeding disorders.

Therapeutic areas: Hematology
Modalities: CRISPR-based therapyGene therapy
Industry: Biotech

Beyond the preview

Go deeper on Fixx Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fixx Pharmaceuticals.

Explore the full profile